Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.

MLA

Heudel, P. E., et al. “Phase II Study of the PI3K Inhibitor BKM120 in Patients with Advanced or Recurrent Endometrial Carcinoma: A Stratified Type I-Type II Study from the GINECO Group.” British Journal of Cancer, vol. 116, no. 3, Jan. 2017, pp. 303–09. EBSCOhost, https://doi.org/10.1038/bjc.2016.430.

APA

Heudel, P.-E., Fabbro, M., Roemer-Becuwe, C., Kaminsky, M. C., Arnaud, A., Joly, F., Roche-Forestier, S., Meunier, J., Foa, C., You, B., Priou, F., Tazi, Y., Floquet, A., Selle, F., Berton-Rigaud, D., Lesoin, A., Kalbacher, E., Lortholary, A., Favier, L., & Treilleux, I. (2017). Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group. British Journal of Cancer, 116(3), 303–309. https://doi.org/10.1038/bjc.2016.430

Chicago

Heudel, P-E, M Fabbro, C Roemer-Becuwe, M C Kaminsky, A Arnaud, F Joly, S Roche-Forestier, et al. 2017. “Phase II Study of the PI3K Inhibitor BKM120 in Patients with Advanced or Recurrent Endometrial Carcinoma: A Stratified Type I-Type II Study from the GINECO Group.” British Journal of Cancer 116 (3): 303–9. doi:10.1038/bjc.2016.430.